期刊文献+

肿瘤诊断^64Cu标记药物临床研究进展 被引量:5

Research Progress of ^64Cu -Radiopharmaceuticalsin Clinical Trial for Tumor Diagnosis
下载PDF
导出
摘要 正电子发射型计算机断层显像(positron emission computed tomography,PET)是核医学重要的诊断及显像工具,具有良好的灵敏度、分辨率和安全性,广泛应用于肿瘤、心脑血管等疾病的诊断。^64Cu核素因其适宜的半衰期(12.7 h)、独特的衰变性质(β^+衰变、β^-衰变、电子俘获),以及可与多种配体配位形成配合物等特点,现已成为PET分子探针及诊疗一体化药物领域的研究热点。目前,有30多项针对^64Cu标记药物的临床研究正在开展,主要集中在神经内分泌肿瘤、肿瘤乏氧、前列腺癌等方面;结果表明,^64Cu标记药物的PET显像具有较高的分辨率、检出率,以及良好的安全性,另外^64Cu相对较长的半衰期使得^64Cu核素及其药物可运输至距离较远的医疗单位,方便药物制备及临床使用。本文对近十年来^64Cu标记药物在肿瘤诊断方面的临床研究进展进行了总结,以期为今后^64Cu标记药物的研发提供参考及思路;预期在不久的未来,将会有^64Cu标记药物获批应用于神经内分泌肿瘤、前列腺癌等疾病的诊断。 Positron computed emission tomography(PET)is an important diagnosis and imaging tool for nuclear medicine with the advantages of high sensitivity,resolution,and safety.It is widely used in the diagnosis of tumors,cardiovascular and cerebrovascular diseases,and so on.^64Cu nuclide has become the focus of research in the field of PET molecular probe and theranostic radiopharmaceuticals due to its suitable half-life(12.7 h),unique decay properties(β^+,0.653 MeV,17.4%;β^-,0.579 MeV,39%;electron capture)and the ability to form stable complexes with multiple ligands.Currently,more than 30 clinical studies of^64Cu-radiopharmaceuticals are on going with focus on neuroendocrine tumors,prostate cancer and hypoxic tumors.The results of these clinical trials of^64Cu-radiopharmaceuticals showed that^64Cu-radiopharmaceuticals had high resolution,detection rate and good safety.In addition,the long half-life of^64Cu nuclide allows^64Cu nuclide and^64Cu-radiopharmaceuticals to be transported to distant medical units,which is convenient for dose preparation and clinical practice.This paper selectively reviewed the progresses in clinical research conducted on^64Cu-radiopharmaceuticals in the past decade,hoping to provide some references and ideas for the future research and development of^64Cu-radiopharmaceuticals.It is expected that^64Cu-radiopharmaceuticals will be approved for the diagnosis of neuroendocrine tumors,prostate cancer and other diseases in the near future.
作者 赵海龙 李洪玉 ZHAO Hailong;LI Hongyu(HTA Co.,Ltd.,Beijing 102413,China)
出处 《同位素》 CAS 2021年第1期78-88,I0006,共12页 Journal of Isotopes
关键词 ^64Cu标记药物 临床研究 神经内分泌肿瘤 乏氧 前列腺癌 ^64Cu-radiopharmaceuticals clinical trial neuroendocrine tumors hypoxia prostate cancer
  • 相关文献

参考文献5

二级参考文献180

  • 1崔海平,王刚,张汉文,解向前,陈玉清,王艳杰,李大康.CYCLONE-30质子回旋加速器的靶系统及生产用靶的制备[J].原子能科学技术,1996,30(1):46-50. 被引量:8
  • 2Shriver D F, Atkin P Ws, Langfore C H.无机化学[M].高忆慈,史启祯,曾克慰,等译.北京:高等教育出版社,1997:130—154.
  • 3Wang J J, Yang C T, Kim Y S, Sreerama S G, Cao Q Z, Li Z B, He Z J, Chen X Y, Liu S. Journal of Medicinal Chemistry, 2007, 50(21): 5057-5069.
  • 4刘锰(LiuM),刘正浩(LiuZH).核化学与放射化学,1999.36-41.
  • 5Cai W B, Guzman R, Hsu A R, Wang H, Chen K, Sun G H, Gera A, Choi R, Bliss T, He L N, Li Z B, Maag A L D, Hori N, Zhao H, Moseley M, Steinberg G K, Chen X Y. Stroke, 2009, 40(1) : 270-277.
  • 6Lahorte C M M, Vanderheyden J L, Steinmetz N, van de Wiele C, Dierckx R A, Slegers G. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 ( 6 ) : 887-919.
  • 7Imam S K. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25 (3) : 365-374.
  • 8Dunphy M P S, Lewis J S. Journal of Nuclear Medicine, 2009, 50:106-121.
  • 9Anderson C J, Ferdani R. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24(4) : 379-393.
  • 10McCarthy D W, Shefer R E, Klinkowstein R E, Bass L A, Margeneau W H, Cutler C S, Anderson C J, Welch M J. Nuclear Medicine and Biology, 1997, 24( 1 ) : 35-43.

共引文献21

同被引文献75

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部